RxDoctor Payments DataLook up a doctor →

David Wang

Clinical Cardiac Electrophysiology · Provo, UTNPI 1649491440

Payments from drug & device makers

$13,499in general payments, 2019–2025

Across 369 payments — averaging $36.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$6K
  • Medtronic$2K
  • Biosense Webster, Inc.$1K
  • Pfizer$690
  • Boehringer Ingelheim$665
  • Johnson & Johnson$426
  • plus $3K from 36 others

What the payments were for

  • Consulting fees$4,89036%
  • Travel & lodging$1,50811%
  • Food & beverage$7,10153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,499 in reported general payments places this provider in the 20th percentile of 29 clinical cardiac electrophysiology providers in Utah.

See all clinical cardiac electrophysiology providers in Utah

Medicare billing

Part B allowed, 2024
$548,202
Medicare patients
1,219
Services billed
7,550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,052$1,159,124
XareltoRivaroxaban317$341,178
Flecainide Acetate752$27,704
SotalolSotalol Hcl974$19,721
Amiodarone Hcl326$7,977
Metoprolol Succinate464$6,971
Dofetilide34$4,443
Propafenone Hcl80$2,787
Metoprolol Tartrate217$2,235
Warfarin Sodium124$1,580
Enoxaparin Sodium20$1,037
Losartan Potassium60$870
Diltiazem Hcl30$865
Potassium Chloride60$814
Lisinopril75$700

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$690$1,159,1241,052 claims
Johnson & JohnsonXarelto$426$341,178317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 29 clinical cardiac electrophysiology providers in Utah.

Other clinical cardiac electrophysiology in Provo

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →